CARsgen Therapeutics Holdings Limited (HKG:2171) shareholders should be happy to see the share price up 26% in the last month. But that is minimal compensation for the share price under-performance over the last year. After all, the share price is down 47% in the last year, significantly under-performing the market.
While the last year has been tough for CARsgen Therapeutics Holdings shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
See our latest analysis for CARsgen Therapeutics Holdings
CARsgen Therapeutics Holdings isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
SEHK:2171 Earnings and Revenue Growth July 20th 2022
Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
A Different Perspective
CARsgen Therapeutics Holdings shareholders are down 47% for the year, even worse than the market loss of 22%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. Putting aside the last twelve months, it's good to see the share price has rebounded by 24%, in the last ninety days. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 4 warning signs we've spotted with CARsgen Therapeutics Holdings .
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
卡斯根治療控股有限公司(HKG:2171)股東應該很高興看到股價在過去一個月上漲了26%。但這是對過去一年股價表現不佳的最低補償。畢竟,該公司股價在過去一年下跌了47%,表現明顯遜於大盤。
雖然過去的一年對CARsgen治療控股公司的股東來説是艱難的一年,但過去的一週顯示出了希望的跡象。因此,讓我們看看較長期的基本面,看看它們是否是負回報的驅動因素。
查看我們對Carsgen Treateutics Holdings的最新分析
Carsgen治療控股公司目前沒有盈利,因此大多數分析師都會關注收入增長,以瞭解基礎業務的增長速度。當一家公司沒有盈利時,我們通常預計會看到良好的收入增長。這是因為,如果一家公司的收入增長微不足道,而且永遠不會盈利,那麼很難相信它會持續下去。
下圖描述了收益和收入隨時間的變化(通過單擊圖像來揭示確切的價值)。
聯交所:2171盈利及收入增長2022年7月20日
資產負債表的強健至關重要。也許很值得一看我們的免費報告其財務狀況如何隨着時間的推移而發生變化。
不同的視角
Carsgen治療控股公司的股東今年以來下跌了47%,甚至比22%的市場跌幅還要糟糕。這令人失望,但值得記住的是,整個市場的拋售不會有任何幫助。拋開過去12個月的情況不談,很高興看到股價在過去90天裏反彈了24%。這可能只是一次反彈,因為拋售過於激進,但祈禱這是一種新趨勢的開始。我發現,把股價作為衡量企業業績的長期指標是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。為此,您應該意識到4個警示標誌我們發現了卡斯根治療控股公司。
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費已證明自己能夠實現盈利增長的公司名單。
請注意,本文引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。